selected publications
- Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma. Blood advances. 2026 Academic Article GET IT
-
A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes.
Blood.
2025
Academic Article
GET IT
Times cited: 4 -
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
Leukemia & lymphoma.
2025
Information Resource
GET IT
Times cited: 6 -
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.
Seminars in hematology.
2024
Information Resource
GET IT
Times cited: 3 - KLRG1, Another Opportunity for a Breakthrough in MTCL. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
-
Approach to High-Risk Multiple Myeloma.
Hematology/oncology clinics of North America.
2024
Information Resource
GET IT
Times cited: 1 -
On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2023
Editorial Article
GET IT
Times cited: 2 -
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2023
Academic Article
GET IT
Times cited: 13 -
Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Hematological oncology.
2023
Information Resource
GET IT
Times cited: 11 -
Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Expert review of anticancer therapy.
2022
Academic Article
GET IT
Times cited: 1 -
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Blood advances.
2021
Academic Article
GET IT
Times cited: 40 -
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Haematologica.
2021
Academic Article
GET IT
Times cited: 35 -
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Blood.
2021
Academic Article
GET IT
Times cited: 103 -
Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
British journal of haematology.
2018
Information Resource
GET IT
Times cited: 22 -
Novel Approaches in Waldenström Macroglobulinemia.
Hematology/oncology clinics of North America.
2018
Information Resource
GET IT
Times cited: 4 -
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Clinical advances in hematology & oncology : H&O.
2016
Information Resource
GET IT
Times cited: 11 -
Ibrutinib in previously treated Waldenström's macroglobulinemia.
The New England journal of medicine.
2015
Academic Article
GET IT
Times cited: 864 -
Hospital room sterilization using far-ultraviolet radiation: a pilot evaluation of the Sterilray device in an active hospital setting.
Infection control and hospital epidemiology.
2013
Academic Article
GET IT
Times cited: 1 -
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
The New England journal of medicine.
2013
Academic Article
GET IT
Times cited: 520 -
Integration of patient-specific paranasal sinus computed tomographic data into a virtual surgical environment.
American journal of rhinology & allergy.
2009
Academic Article
GET IT
Times cited: 31